Published on 2 Mar 2024 on Simply Wall St. via Yahoo Finance
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their...
Last week saw the newest full-year earnings release from Amicus Therapeutics, Inc. (NASDAQ:FOLD), an important milestone in the company's journey to build a stronger business. The statutory results were not great - while revenues of US$399m were in line with expectations,Amicus Therapeutics lost US$0.51 a share in the process. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Amicus Therapeutics after the latest results.
See our latest analysis for Amicus Therapeutics
